CONFERENCES

      Adverse Outcome Pathways Community of Practice Symposium

      AOP Community of Practice Symposium is an annual conference that focuses on the use of adverse outcome pathways (AOPs) in toxicology. AOPs are a conceptual framework that describes the sequence of events leading from a molecular initiating event to an adverse outcome at the level of the organism. The symposium covers topics such as AOP development, validation, and regulatory applications. The aim of the symposium is to promote the use of AOPs to improve the efficiency and accuracy of chemical safety testing, and to provide a forum for sharing knowledge and collaborating on the use of AOPs. The symposium is aimed at toxicologists, regulators, and other professionals involved in chemical safety assessment.

      AOP Symposium 2022

      Date

      Feb 15, 2022 - Feb 22, 2022

      Location

      Online

      At this symposium, AOP developers, coaches and reviewers share their experiences in portraying scientifically credible linkages between perturbations of biological systems and adverse effects on human health. 

      PMIScience.com is operated by Philip Morris International for the purpose of publishing and disseminating scientific information about Philip Morris International’s efforts in support of its smoke-free product portfolio. This site is a global site for use by scientists, the public health and regulatory communities, and other stakeholders with an interest in tobacco policy. The purpose of this site is not advertising or marketing, nor is it directed at any specific market. It is not intended for use by consumers. New tobacco products sold in the United States are subject to FDA regulation; therefore the content of this site is not intended to make, and nor should it be construed as making, any product related claims in the United States without proper FDA authorization. ​
      ​
      Reduced Risk Products ("RRPs”) is the term we use to refer to products that present, are likely to present, or have the potential to present less risk of harm to smokers who switch to these products versus continuing smoking. PMI has a range of RRPs in various stages of development, scientific assessment and commercialization. All of our RRPs are smoke-free products that deliver nicotine with far lower quantities of harmful and potentially harmful constituents than found in cigarette smoke.